Evaluation of biocatalyzed cannabionoid extracts

植物大麻素因其作为治疗多种疾病的潜在药物而受到相当大的关注。虽然它们是天然存在的，但CMH生物技术公司已经获得了使用单细胞生物对大麻素进行生物催化的过程的专利，从而以相对高的纯度生产大量的大麻素，这些大麻素可以用于分析参考物质和药用级大麻素。生物合成已被观察到是非特异性的许多小大麻素被生产。该资助的目的是评估生物合成途径中产生的这些低水平代谢物的结构，并确定它们是天然存在的还是具有潜在治疗活性的新化合物。这种合作关系将结合生物技术和先进的分析化学，以更好地了解大麻素生物催化的影响。

Phytocannabinoids have received considerable attention due to their potential as therapeutic agents for a widevariety of ailments. Although they are naturally occurring, CMH Biotechnologies Inc. has patented the processof biocatalysis of cannabinoids using single-celled organisms, thereby producing large amounts of thesecannabinoids in relatively high purity, which can be used for analytical reference materials and aspharmaceutical grade cannabinoids. The biosynthesis has been observed to be non-specific with many minorcannabinoids being produced. The purpose of this Engage grant is to evaluate the structures of these low-levelmetabolites being produced in the biosynthetic pathways and establish whether they are naturally occurring ornovel compounds with potential therapeutic activity. This partnership will combine biotechnology andadvanced analytical chemistry for a better understanding of the impacts on cannabinoid biocatalysis.